Pd-Rx Pharmaceutical
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company offers prepackaged medications, such as creams, ointments, ophthalmics, otics, liquids, and suspension products. It also provides packaging services. In addition, the company offers a dispensing platform, a manual dispensing s… Read more
Pd-Rx Pharmaceutical (PDRX) - Total Liabilities
Latest total liabilities as of June 2016: $2.02 Million USD
Based on the latest financial reports, Pd-Rx Pharmaceutical (PDRX) has total liabilities worth $2.02 Million USD as of June 2016.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pd-Rx Pharmaceutical - Total Liabilities Trend (2013–2025)
This chart illustrates how Pd-Rx Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pd-Rx Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Pd-Rx Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Iren SpA
MU:TZ8
|
Germany | €8.74 Billion |
|
Harbin Electric Co Ltd
STU:HP6H
|
Germany | €56.71 Billion |
|
ASOS (DYQ.SG)
STU:DYQ
|
Germany | €1.75 Billion |
|
123fahrschule SE
DU:123F
|
Germany | €10.44 Million |
|
Mobile Max-M
TA:MBMX
|
Israel | ILA2.40 Million |
|
Telecom Egypt Company S.A.E
LSE:TEEG
|
UK | $141.41 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Pd-Rx Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pd-Rx Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pd-Rx Pharmaceutical (2013–2025)
The table below shows the annual total liabilities of Pd-Rx Pharmaceutical from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $1.74 Million | -26.64% |
| 2024-06-30 | $2.37 Million | +39.61% |
| 2023-06-30 | $1.70 Million | -8.79% |
| 2022-06-30 | $1.86 Million | -23.47% |
| 2021-06-30 | $2.43 Million | +12.14% |
| 2020-06-30 | $2.17 Million | +29.37% |
| 2019-06-30 | $1.68 Million | -12.50% |
| 2018-06-30 | $1.92 Million | +47.62% |
| 2017-06-30 | $1.30 Million | -35.91% |
| 2016-06-30 | $2.02 Million | +68.37% |
| 2015-06-30 | $1.20 Million | -3.47% |
| 2014-06-30 | $1.25 Million | -62.90% |
| 2013-06-30 | $3.36 Million | -- |